<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067688</url>
  </required_header>
  <id_info>
    <org_study_id>YHP1604-301</org_study_id>
    <nct_id>NCT03067688</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Temisartan/Amlodipine &amp; Rosuvastatin in Subjects With Hypertension and Hyperlipidemia</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy
      and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with
      hypertension and hyperlipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a phase 3 study to evaluate efficacy and safety of co-administrated
      temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

      In &quot;Temisartan/Amlodipine/Rosuvastatin&quot; treatment group, 60 subjects will be assigned and the
      subjects administer &quot;Temisartan/Amlodipine/Rosuvastatin&quot; 8 for weeks.

      In &quot;Temisartan/Amlodipine&quot; treatment group, 60 subjects will be assigned and the subjects
      administer &quot;Temisartan/Amlodipine&quot; for 8 weeks.

      In &quot;Temisartan/Rosuvastatin&quot; treatment group, 60 subjects will be assigned and the subjects
      administer &quot;Temisartan/Rosuvastatin&quot; for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sitting systolic blood pressure (MSSBP)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MSSBP change form the baseline at Week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>LDL-C change form the baseline at Week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSSBP (Mean sitting systolic blood pressure)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>MSSBP change form the baseline at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sitting diastolic blood pressure (MSDBP)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>MSDBP change form the baseline at Week 4, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>LDL-C change form the baseline at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>TC change form the baseline at Week 4, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>HDL-C change form the baseline at Week 4, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein cholesterol/High density lipoprotein cholesterol (LDL-C/HDL-C)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>LDL-C/HDL-C change form the baseline at Week 4, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol/High density lipoprotein cholesterol (TC/HDL-C)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>TC/HDL-C change form the baseline at Week 4, 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TG)</measure>
    <time_frame>Baseline, Week 4, Week 8</time_frame>
    <description>TG change form the baseline at Week 4, 8</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>&quot;Combination drug:Temisartan+Amlodipine+Rosuvastatin&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects will be assigned and the subjects will be administered &quot;Temisartan+Amlodipine+Rosuvastatin&quot; for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temisartan+Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 subjects will be assigned and the subjects will be administered &quot;Twynsta Tab.(Temisartan+Amlodipine)&quot; for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temisartan+Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 subjects will be assigned and the subjects will be administered &quot;Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin)&quot; for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temisartan+Amlodipine+Rosuvastatin (Combination drug)</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>&quot;Combination drug:Temisartan+Amlodipine+Rosuvastatin&quot;</arm_group_label>
    <other_name>Twynsta Tab.+Crestor Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temisartan+Amlodipine</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Temisartan+Amlodipine</arm_group_label>
    <other_name>Twynsta Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temisartan+Rosuvastatin</intervention_name>
    <description>PO, Once daily(QD), 8weeks</description>
    <arm_group_label>Temisartan+Rosuvastatin</arm_group_label>
    <other_name>Micardis Tab.+Crestor Tab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Subjects with hypertension and hyperlipidemia

        Exclusion Criteria:

          1. Patients with known or suspected secondary hypertension

          2. Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyunhee Na, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yuhan Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunhee Na, MD</last_name>
    <phone>+82-2-828-0352</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Natuional University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyosoo Kim, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>April 16, 2017</last_update_submitted>
  <last_update_submitted_qc>April 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

